MicroPort® EP Obtains Approval for its Medical Consumables and Equipment in Egypt

Shanghai, China, 24 February 2021 — Shanghai MicroPort EP MedTech Co., Ltd. (“MicroPort® EP has recently obtained registration approval by the Egyptian Drug Authority (EDA) for its proprietary catheters, sheaths and other equipment, marking its first entry into the Egyptian market.

The catheters and equipment approved for use in Egypt are intended for the quick diagnosis and effective treatment of arrhythmias. Those approved include FireMagic® Cardiac RF Ablation Catheter, FireMagic™ 3D Irrigated Ablation Catheter, EasyFinder® Fixed Curve Diagnostic Catheter, EasyFinder® Steerable Curve Diagnostic Catheter, EasyLoop® Circular Mapping Catheter, PathBuilder® Transseptal Guiding Introducer, Columbus® 3D EP Navigation System, Columbus® Cardiac Electrophysiology Stimulator, OptimAblate® Cardiac RF Generator and OptimAblate® Irrigation Pump.

The approval of these products in Egypt marks the official entry of MicroPort® EP in the Egyptian market and its further expansion in Africa, providing local patients and doctors with a comprehensive integrated medical solution for cardiac electrophysiology.

Arrhythmia refers to an abnormal change in the normal heart rhythm. It is a common cardiovascular disease, and severe arrhythmia is a major cause of sudden cardiac death. Compared with conventional pharmacological therapies, which can only contain arrhythmias to a certain extent, the cardiac radiofrequency (RF) ablation procedure is a more effective non-pharmacological method that blocks the arrhythmia-causing abnormal bundle branch and site of origin by releasing RF currents from an electrode catheter to a specific position of the heart chamber. Currently, RF ablation is the preferred procedure for the radical treatment of tachyarrhythmia.

About MicroPort® EP

Shanghai MicroPort EP MedTech Co., Ltd. (“MicroPort® EP”) is a subsidiary of Shanghai MicroPort Medical (Group) Co., Ltd. (“MicroPort®”, stock code: 00853.HK). MicroPort® EP's product portfolio aims to provide doctors and patients with systematic integrated solution to electrophysiological interventional procedures, which has allowed the company to make high precision electrophysiology product more accessible for patients across the globe.